Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New daily pill shows promise for weight loss in Mid-Stage trial

NCT ID NCT06693843

Disease control Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study tests an experimental daily pill called aleniglipron for weight loss in 220 adults with obesity or overweight who also have a weight-related health issue. Participants receive either the drug or a placebo for 36 weeks, with the option to continue on the drug for another 36 weeks. The main goal is to see how much weight people lose and how safe the drug is.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
aleniglipron (GSBR-1290)
What this could lead to
If successful, this could provide a new oral medication to help people with obesity or overweight lose significant weight and improve related health conditions.
What could go wrong
This is an early Phase 2b trial with only 220 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

230 people

The number who actually took part.

Started

Oct 2024

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent * BMI ≥30 kg/m2 or BMI ≥27.0 kg/m2 and previous/current diagnosis of ≥ 1 obesity related comorbidity Exclusion Criteria: * Previous documented diagnosis of diabetes mellitus. * Self-reported change in body weight \>5% within 3 months before Screening * Body weight ≤80 kg at Screening * Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \>1 year prior to screening)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity, overweight, or chronic weight management

Contacts and locations

Locations

  • ACCESS Research Site

    Phoenix, Arizona, 85044, United States

  • ACCESS Research Site

    Anaheim, California, 92801, United States

  • ACCESS Research Site

    Los Angeles, California, 90057, United States

  • ACCESS Research Site

    Montclair, California, 91763, United States

  • ACCESS Research Site

    Rancho Cucamonga, California, 91730, United States

  • ACCESS Research Site

    Sacramento, California, 95821, United States

  • ACCESS Research Site

    Spring Valley, California, 91978, United States

  • ACCESS Research Site

    Honolulu, Hawaii, 96814, United States

  • ACCESS Research Site

    Chicago, Illinois, 60602, United States

  • ACCESS Research Site

    Chicago, Illinois, 60637, United States

  • ACCESS Research Site

    Evanston, Illinois, 60201, United States

  • ACCESS Research Site

    Muncie, Indiana, 47304, United States

  • ACCESS Research Site

    Valparaiso, Indiana, 46383, United States

  • ACCESS Research Site

    West Des Moines, Iowa, 50265, United States

  • ACCESS Research Site

    Baton Rouge, Louisiana, 70808, United States

  • ACCESS Research Site

    Richfield, Minnesota, 55423, United States

  • ACCESS Research Site

    City of Saint Peters, Missouri, 63303, United States

  • ACCESS Research Site

    Hazelwood, Missouri, 63042, United States

  • ACCESS Research Site

    Springfield, Missouri, 65807, United States

  • ACCESS Research Site

    Albany, New York, 12203, United States

  • ACCESS Research Site

    Binghamton, New York, 13905, United States

  • ACCESS Research Site

    Brooklyn, New York, 10016, United States

  • ACCESS Research Site

    Rochester, New York, 14609, United States

  • ACCESS Research Site

    Wilmington, North Carolina, 28403, United States

  • ACCESS Research Site

    Cincinnati, Ohio, 45219, United States

  • ACCESS Research Site

    Norman, Oklahoma, 73069, United States

  • ACCESS Research Site

    Medford, Oregon, 97504, United States

  • ACCESS Research Site

    Pittsburgh, Pennsylvania, 15236, United States

  • ACCESS Research Site

    Moncks Corner, South Carolina, 29461, United States

  • ACCESS Research Site

    Chattanooga, Tennessee, 37421, United States

  • ACCESS Research Site

    Austin, Texas, 78704, United States

  • ACCESS Research Site

    Austin, Texas, 78731, United States

  • ACCESS Research Site

    Dallas, Texas, 75226, United States

  • ACCESS Research Site

    Dallas, Texas, 75243, United States

  • ACCESS Research Site

    Mesquite, Texas, 75149, United States

  • ACCESS Research Site

    Shavano Park, Texas, 78231, United States

  • ACCESS Research Site

    West Jordan, Utah, 84088, United States

  • ACCESS Research Site

    Winchester, Virginia, 22601, United States

  • ACCESS Research Site

    Morgantown, West Virginia, 26505, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.